Jennifer P King

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 11

Top Topics

Placebo Controlled

Respiratory Syndrome Coronavirus

Top Venues

Influenza and other respiratory viruses

Human vaccines & immunotherapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Thomas G Boyce, Min Z Levine, David L McClure, Jennifer P King, Brendan Flannery, Huong Q Nguyen, Edward A Belongia
Antibody response to sequential vaccination with cell culture, recombinant, or egg-based influenza vaccines among U.S. adults. Human vaccines & immunotherapeutics 20 (1) (2024)
Thomas G Boyce, Min Z Levine, David L McClure, Jennifer P King, Brendan Flannery, Huong Q Nguyen, Edward A Belongia
Antibody response to sequential vaccination with cell culture, recombinant, or egg-based influenza vaccines among U.S. adults. Human vaccines & immunotherapeutics 20 (1) (2024)
Thomas G Boyce, Min Z Levine, David L McClure, Jennifer P King, Brendan Flannery, Huong Q Nguyen, Edward A Belongia
Antibody response to sequential vaccination with cell culture, recombinant, or egg-based influenza vaccines among U.S. adults. Human vaccines & immunotherapeutics 20 (1) (2024)
Thomas G Boyce, Min Z Levine, David L McClure, Jennifer P King, Brendan Flannery, Huong Q Nguyen, Edward A Belongia
Antibody response to sequential vaccination with cell culture, recombinant, or egg-based influenza vaccines among U.S. adults. Human vaccines & immunotherapeutics 20 (1) (2024)
Joshua G Petrie, Jennifer P King, David L McClure, Melissa A R Rolfes, Jennifer K Meece, David Pattinson, Gabriele Neumann, Yoshihiro Kawaoka, Edward A Belongia, Huong Q McLean
Effectiveness of first and second COVID-19 mRNA vaccine monovalent booster doses during a period of circulation of Omicron variant sublineages: December 2021-July 2022. Influenza and other respiratory viruses 17 (3) (2023)
Joshua G Petrie, Jennifer P King, David L McClure, Melissa A R Rolfes, Jennifer K Meece, David Pattinson, Gabriele Neumann, Yoshihiro Kawaoka, Edward A Belongia, Huong Q McLean
Effectiveness of first and second COVID-19 mRNA vaccine monovalent booster doses during a period of circulation of Omicron variant sublineages: December 2021-July 2022. Influenza and other respiratory viruses 17 (3) (2023)
Joshua G Petrie, Jennifer P King, David L McClure, Melissa A R Rolfes, Jennifer K Meece, David Pattinson, Gabriele Neumann, Yoshihiro Kawaoka, Edward A Belongia, Huong Q McLean
Effectiveness of first and second COVID-19 mRNA vaccine monovalent booster doses during a period of circulation of Omicron variant sublineages: December 2021-July 2022. Influenza and other respiratory viruses 17 (3) (2023)
Huong Q Nguyen, David L McClure, Jennifer P King, Jennifer K Meece, David J Pattinson, Gabriele Neumann, Yoshihiro Kawaoka, Melissa A R Rolfes, Edward A Belongia
mRNA COVID-19 vaccine effectiveness against SARS-CoV-2 infection in a prospective community cohort, rural Wisconsin, November 2020 to December 2021. Influenza and other respiratory viruses 16 (4) (2022)
Jessie R Chung, Sara S Kim, Edward A Belongia, Huong Q McLean, Jennifer P King, Mary Patricia Nowalk, Richard K Zimmerman, Krissy Moehling Geffel, Emily T Martin, Arnold S Monto, Lois E Lamerato, Manjusha Gaglani, Eric Hoffman, Marcus Volz, Michael L Jackson, Lisa A Jackson, Manish M Patel, Brendan Flannery
Vaccine effectiveness against COVID-19 among symptomatic persons aged ≥12 years with reported contact with COVID-19 cases, February-September 2021. Influenza and other respiratory viruses 16 (4) (2022)
Jennifer P King, Huong Q McLean, Edward A Belongia
Risk of symptomatic severe acute respiratory syndrome coronavirus 2 infection not associated with influenza vaccination in the 2019-2020 season. Influenza and other respiratory viruses 15 (6) (2021)
Jennifer P King, Huong Q McLean, Edward A Belongia
Validation of self-reported influenza vaccination in the current and prior season. Influenza and other respiratory viruses 12 (6) (2018)